30 Opioid Alternative Chronic Pain Management Trends

‍Data-driven analysis of the shift from opioid-first prescribing to behavioral, integrative, and non-pharmacological chronic pain treatment in the United States

Chronic pain affects 24.3% of US adults, yet the way clinicians approach treatment is changing rapidly. Opioid prescriptions have declined 52% since 2012, supported by growing evidence that non-opioid therapies can match or outperform opioids for many chronic pain conditions. Clinical guidelines from the CDC, ACP, and APA now recommend non-pharmacological approaches as first-line treatment.

The following 30 statistics capture this transformation, from the scale of the crisis to the therapies, policies, and economic forces reshaping chronic pain care.

Key Takeaways

• Chronic pain affects roughly 1 in 4 US adults, costing over $635 billion annually in healthcare spending and lost productivity.
• Opioid prescriptions have declined 52% since 2012, and drug overdose deaths fell 26.2% in 2024.
• The CDC, ACP, and APA now recommend non-pharmacological therapies as first-line treatment for most chronic pain conditions.
• Behavioral therapies like PRT show durable results, with over half of participants remaining pain-free at 5-year follow-up in a randomized controlled trial.
• Replacing 10% of inappropriate opioid use with alternatives could prevent 323,000 OUD cases and save $88 billion over 15 years.

Chronic Pain Prevalence and Burden Statistics

1. 24.3% of US adults reported chronic pain in 2023

Nearly 1 in 4 American adults, approximately 62.7 million people, reported chronic pain in the past 3 months according to the 2023 National Health Interview Survey. This baseline figure establishes why the search for effective alternatives to opioid therapy has become a clinical priority. Chronic pain prevalence increases with age, rising to 33.4% among adults aged 65 and older.

2. 8.5% of US adults live with high-impact chronic pain

Beyond the broader prevalence figure, 8.5% of adults, roughly 22 million people, experience high-impact chronic pain that frequently limits life or work activities. This subpopulation carries the heaviest treatment burden and faces the highest risk of opioid dependence. For these patients, comprehensive non-opioid approaches that address function alongside pain intensity are especially relevant.

3. Chronic pain costs the US over $635 billion annually

The economic burden of chronic pain costs over $635 billion in direct healthcare spending and lost productivity, surpassing the combined costs of heart disease, cancer, and diabetes care. More recent analyses presented at ISPOR 2024 estimate over $725 billion when accounting for updated healthcare costs. These figures underscore why investing in effective non-opioid approaches is both a clinical and fiscal imperative.

4. 40% of adults with chronic pain have comorbid depression or anxiety

A 2025 systematic review and meta-analysis spanning 376 studies and 347,468 individuals found that roughly 40% of patients with chronic pain experience clinically significant depression or anxiety. This high comorbidity rate helps explain why behavioral therapies that address both psychological distress and pain, such as CBT, EAET, and ACT, often outperform purely pharmacological interventions.

Opioid Prescribing Trends: The Decline in Numbers

5. Opioid prescriptions declined 52% from their 2012 peak

Total opioid prescriptions dispensed in the US dropped to 125.7 million in 2024, down from 260.5 million at the 2012 peak, a 52% decline. This sustained decrease reflects a fundamental shift in how clinicians approach pain management, driven by updated guidelines, prescriber education, and expanded access to non-opioid therapies.

6. Per-capita opioid dispensing rate dropped 56%

The national opioid dispensing rate fell to 35.4 per 100 persons by 2024, down from 46.8 in 2019. From the 81.3 per 100 peak in 2012, this represents a 56% per-capita reduction. Every US state recorded decreases during this period, ranging from 36% to 68%.

7. Drug overdose deaths fell 26.2% in 2024

Estimated drug overdose deaths fell 26.2% in 2024, from 105,007 in 2023 to 79,384. Opioid-involved deaths also declined significantly during this period. This represents one of the largest single-year decreases in overdose deaths since systematic tracking began, though the numbers remain historically elevated.

8. 8 to 12% of patients on long-term opioids develop opioid use disorder

An estimated 8 to 12% of patients prescribed long-term opioid therapy for chronic pain develop opioid use disorder. In 2024, 4.8 million had OUD in the US, and 7.6 million misused prescription opioids. This ongoing risk is a core reason that clinical guidelines now favor non-opioid first-line treatment.

9. Opioids were not superior to non-opioid medications for chronic pain in a 12-month trial

In a 12-month VA randomized trial of 240 patients with chronic back, hip, or knee pain, opioid therapy was not superior to non-opioid medication for pain-related function. The non-opioid group actually reported significantly better pain intensity scores and fewer adverse effects. This trial, one of the few head-to-head comparisons in the published literature, remains a foundational reference for the shift toward non-opioid pain treatment approaches.

Clinical Guidelines: The Non-Opioid First-Line Consensus

10. The CDC's 2022 guideline includes 12 recommendations prioritizing non-opioid therapies

The CDC's 2022 Clinical Practice Guideline for Prescribing Opioids prioritizes non-opioid therapies for acute, subacute, and chronic pain, stating that opioids should not be considered first-line treatment. The guideline covers 12 recommendations across 4 clinical domains, replacing the more limited 2016 version. It explicitly notes that nonopioid therapies are "at least as effective as opioids for many common types of acute pain."

11. The ACP recommends non-pharmacological treatment first for chronic low back pain

The American College of Physicians recommends that clinicians select non-drug therapy first for chronic low back pain, listing exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, CBT, and spinal manipulation as first-line options. This strong recommendation, supported by moderate-quality evidence, carries particular weight for back pain, the most common chronic pain condition and the leading driver of opioid prescribing.

12. The APA's 2024 guideline identifies CBT and exercise as having strong evidence

The American Psychological Association's 2024 Clinical Practice Guideline for Nonpharmacological Treatment of Chronic Musculoskeletal Pain identifies CBT and exercise as having strong evidence for improving pain outcomes. Based on three systematic reviews including AHRQ evidence, this guideline reinforces the growing consensus that behavioral approaches should be central to chronic pain treatment, not supplementary to it.

13. Zero studies have evaluated long-term opioid therapy outcomes beyond one year

A systematic review conducted for the NIH Pathways to Prevention workshop found no long-term opioid evidence evaluating outcomes beyond one year for pain, function, quality of life, or risk of addiction. This evidence gap is striking given that chronic pain, by definition, persists for months to years. The absence of long-term data supporting opioids contrasts with growing long-term evidence for behavioral and integrative therapies.

Health System Transformation: Institutions Leading the Shift

14. The VA reduced veterans receiving opioid prescriptions by 67%

The Department of Veterans Affairs cut opioid prescriptions 67%, from 874,897 in 2012 to 288,820 in 2023. Long-term opioid use dropped 71%. Concurrent opioid-benzodiazepine prescribing, a particularly dangerous combination, declined 90%. The VA's Opioid Safety Initiative is one of the largest system-level demonstrations that opioid prescribing can be substantially reduced while maintaining or improving pain care quality.

15. The Joint Commission mandated non-pharmacological pain treatment options in 2018

Effective January 1, 2018, the Joint Commission revised its pain management standards to mandate non-pharmacological options, including physical therapy, relaxation techniques, and cognitive-behavioral approaches. Hospitals must also establish protocols for safe opioid prescribing and monitoring. This accreditation requirement applies to more than 22,000 healthcare organizations and pushed non-opioid options from optional to mandatory.

16. Non-pharmacologic therapy adoption rose while opioid use dropped sharply between 2012 and 2019

Among privately insured adults with chronic non-cancer pain, non-pharmacologic therapy use rose from 62.4% to 66.1% between 2012 and 2019, while the proportion receiving any opioid decreased from 49.7% to 30.5%. This dual trend, captured in claims data, shows the substitution pattern playing out in real-world clinical practice, not just in guidelines.

Behavioral and Psychological Pain Therapy Statistics

17. 66% of Pain Reprocessing Therapy participants became pain-free or nearly pain-free

In a randomized controlled trial of 151 adults with chronic back pain (average duration: 10 years), 66% became pain-free or nearly pain-free after 4 weeks of treatment, compared to 20% in the placebo group and 10% in usual care. PRT works by helping patients reappraise chronic pain as a reversible brain process rather than evidence of tissue damage. Lin Health's approach is based on PRT research.

18. PRT results persisted at 5-year follow-up without booster sessions

A 5-year follow-up of the original PRT trial found that over half remained pain-free or nearly pain-free, with no booster sessions required. This durability finding is notable because it suggests that PRT may produce lasting neuroplastic changes rather than temporary symptom relief. Few chronic pain interventions, pharmacological or otherwise, have demonstrated this level of sustained benefit.

19. EAET achieved 63% clinically significant pain reduction versus 17% for CBT in veterans

In a 2024 randomized trial of 126 older veterans with chronic musculoskeletal pain, 63% achieved pain reduction at a clinically significant level (30% or greater) versus only 17% of those receiving CBT. At 6-month follow-up, 41% of EAET participants versus 14% of CBT participants maintained their improvement. Emotional Awareness and Expression Therapy helps patients process unresolved emotions that may contribute to chronic pain.

20. CBT produces consistent beneficial effects on pain, disability, and distress

A Cochrane systematic review with a large evidence base found that CBT reduces pain and disability as well as psychological distress, with small but statistically significant effects compared with usual care or active controls for adults with chronic non-cancer pain. Effects were generally maintained at follow-up. While individual effect sizes are modest, CBT's broad applicability across multiple pain conditions and its strong safety profile make it a foundational component of non-opioid pain care.

21. ACT demonstrates medium effect sizes for pain interference and functional impairment

An overview of 9 systematic reviews encompassing 84 meta-analyses found that Acceptance and Commitment Therapy produces medium effects on pain interference, functional impairment, and depression following treatment. At 3-month follow-up, the effect on functional impairment was large. ACT takes a different approach than CBT, focusing on psychological flexibility and values-driven activity rather than directly challenging pain-related thoughts.

Integrative and Pharmacological Alternatives

22. Acupuncture outperformed sham and no-treatment controls in a 20,827-patient meta-analysis

An individual patient data meta-analysis covering 39 randomized trials and 20,827 patients found that acupuncture outperformed control groups for back and neck pain, osteoarthritis, and chronic headache. Effect sizes were approximately 0.5 standard deviations versus no treatment and 0.2 versus sham. This is the largest acupuncture analysis to date and is frequently cited in clinical guideline development.

23. Tai chi matched or outperformed aerobic exercise for fibromyalgia symptom severity

In a randomized trial of 226 fibromyalgia patients, tai chi matched exercise and in some measures outperformed it at reducing fibromyalgia symptom severity at 24 weeks, with sustained improvement at 52 weeks. This finding is significant because aerobic exercise is already an established treatment for fibromyalgia. Tai chi's combination of gentle movement, mindfulness, and breathing may offer additional mind-body benefits that pure aerobic exercise does not.

24. Interdisciplinary pain rehabilitation programs achieve opioid discontinuation rates exceeding 75%

Systematic reviews of interdisciplinary pain rehabilitation programs show high opioid discontinuation rates, frequently exceeding 75%, with individual program rates ranging from 29% to 100%. Programs at Mayo Clinic report 78% opioid abstinence at both 6- and 12-month follow-up. These programs combine physical therapy, psychological treatment, and medical management into a coordinated approach that addresses chronic pain from multiple angles simultaneously.

25. 65% of fibromyalgia patients reported benefit from low-dose naltrexone

A Mayo Clinic retrospective analysis of 115 patients with fibromyalgia and other chronic pain conditions found that 65% reported symptomatic benefit from low-dose naltrexone, with only 11% reporting adverse effects. LDN is thought to work through anti-inflammatory and immune-modulating mechanisms at doses far below those used for opioid use disorder treatment. While larger randomized trials are needed, early evidence positions LDN as a non-opioid pharmacological option.

Policy, Innovation, and the Economic Case for Non-Opioid Care

26. The FDA approved the first new non-opioid analgesic class in over two decades

On January 30, 2025, the FDA approved suzetrigine (Journavx), a novel non-opioid analgesic (NaV1.8 sodium channel inhibitor) for moderate-to-severe acute pain in adults. This is the first novel non-opioid analgesic mechanism approved in approximately 25 years. Clinical trials involving more than 2,000 patients demonstrated efficacy comparable to existing options without opioid-class risks. The approval signals renewed pharmaceutical investment in non-addictive pain treatments.

27. The NIH HEAL Initiative has invested over $3 billion across 1,800+ projects

The NIH Helping to End Addiction Long-term Initiative has invested over $3 billion across 1,800 research projects in all 50 states, resulting in more than 40 investigational new drug and device designations from the FDA. HEAL funds both new non-addictive pain therapies and improved addiction treatment approaches. This level of federal research investment reflects the scale of commitment to finding alternatives to opioid-based pain management.

28. The NOPAIN Act mandates separate Medicare reimbursement for non-opioid pain treatments

Effective January 1, 2025, the Non-Opioids Prevent Addiction in the Nation Act mandates separate Medicare payment for qualifying non-opioid drugs and devices used in outpatient surgical settings. CMS identified several qualifying non-opioid drugs and devices for separate payment. At least 8 states mandate coverage of non-opioid pain treatments through private insurers, signaling a broader shift in reimbursement policy.

29. The opioid crisis is projected to cost $5.8 trillion over the next 15 years

A 2025 modeling study in the Journal of Medical Economics projects $5.8 trillion in cumulative opioid crisis costs from 2025 to 2039, including $1.8 trillion in healthcare costs, $3.4 trillion in lost productivity, and $700 billion in societal costs. Annual costs are projected to rise from $367 billion in 2025 to $412 billion by 2039. These projections make the economic case for prevention through non-opioid alternatives difficult to ignore.

30. Replacing 10% of opioid use with non-opioid therapies could prevent 323,000 OUD cases and save $88 billion

The same modeling study found that replacing 10% of opioids with non-opioid therapies from 2025 to 2039 could prevent 323,000 opioid use disorder cases, avert 11,000 overdose deaths, and save $88 billion. At 25% replacement, the projections rise to 808,000 OUD cases prevented, 27,000 deaths averted, and $221 billion saved. Even modest shifts in prescribing patterns produce outsized population-level benefits.

How Lin Health Helps with Chronic Pain

The statistics above reflect a clear clinical consensus: non-opioid, non-pharmacological approaches should be the starting point for chronic pain treatment. Lin Health's program is built on this evidence base, applying a brain-first pain approach that addresses the neuroplastic mechanisms underlying persistent pain.

Chronic pain often involves a nervous system that has become sensitized, continuing to produce pain signals even after an initial injury has healed. Lin Health's program helps participants retrain these pain pathways through behavioral and psychological approaches, including CBT, ACT, EAET, somatic tracking, and techniques based on Pain Reprocessing Therapy research.

The program is delivered through trained recovery coaches paired with an app-based curriculum, designed to work alongside (not replace) existing medical care. Lin Health treats lower back pain, fibromyalgia, chronic migraine, neck pain, shoulder pain, and other chronic pain conditions.

Lin Health collaborates with health systems including Mayo Clinic and WellSpan to deliver behavioral pain care to patients who may benefit from non-opioid approaches.

If you or a patient are exploring non-opioid options for chronic pain, Lin Health's program is covered by most major insurance plans in CO, TX, FL, CA, and NY, with short wait times and often a same-day callback. Check your eligibility.

Frequently Asked Questions

What are the most effective non-opioid treatments for chronic pain?

Behavioral therapies (CBT, PRT, EAET, ACT), physical therapy, acupuncture, exercise, and multidisciplinary rehabilitation programs have the strongest evidence. The CDC, ACP, and APA all recommend non-pharmacological approaches as first-line treatment. For pharmacological alternatives, SNRIs like duloxetine, gabapentinoids, and low-dose naltrexone may help for specific conditions. The right approach depends on the individual's pain condition, and a coordinated plan with a clinician is recommended.

How much have opioid prescriptions declined in the US?

Opioid prescriptions have declined 52% since their 2012 peak, dropping from 260.5 million to approximately 125.7 million in 2024. The per-capita dispensing rate fell 56%, from 81.3 to 35.4 prescriptions per 100 persons. Every US state recorded decreases ranging from 36% to 68% during this period, reflecting both updated clinical guidelines and state-level policy changes.

Do clinical guidelines recommend non-opioid treatments over opioids?

Yes. The CDC's 2022 Clinical Practice Guideline, the American College of Physicians, and the American Psychological Association all recommend non-pharmacological therapies as first-line treatment for chronic pain. The VA and Joint Commission have implemented similar standards. These guidelines cite evidence that non-opioid therapies can match or exceed opioid effectiveness for many chronic pain conditions while carrying fewer risks.

What is Pain Reprocessing Therapy and how effective is it?

Pain Reprocessing Therapy is a psychological treatment that helps patients reappraise chronic pain as a reversible brain process rather than a sign of tissue damage. In a randomized controlled trial of adults with chronic back pain, 66% of participants became pain-free or nearly pain-free after 4 weeks. A 5-year follow-up found that over half maintained those results without additional treatment sessions.

Does insurance cover non-opioid pain treatments?

Coverage is expanding. The NOPAIN Act (effective January 2025) mandates separate Medicare reimbursement for non-opioid pain treatments. At least 8 states require private insurers to cover non-opioid alternatives. Many behavioral pain programs, including Lin Health, are covered by major insurance carriers in CO, TX, FL, CA, and NY. Check with your specific plan for coverage details.

What is the economic cost of chronic pain in the United States?

Chronic pain costs the US an estimated $635 billion or more annually in direct healthcare spending and lost productivity, exceeding the combined costs of heart disease, cancer, and diabetes care. The opioid crisis specifically is projected to cost $5.8 trillion over the next 15 years. Models suggest that replacing even 10% of inappropriate opioid prescriptions with non-opioid therapies could save $88 billion.

This article is for informational purposes and is not medical advice. Consult a qualified healthcare provider before making any changes to your pain treatment plan. Lin Health's program is designed to complement, not replace, medical care from your clinician.